Combined Analysis of Estrogen Receptor β-1 and Progesterone Receptor Expression Identifies Lung Cancer Patients with Poor Outcome

Purpose: Steroid hormones and growth factors affect lung cancer, and it is possible they act in concert to influence patient outcome. Experimental Design: Primary lung tumors and normal lung tissue were analyzed for expression and localization of estrogen receptor α and β-1 (ERα and ERβ), aromatase, progesterone receptor (PR), and epidermal growth factor receptor (EGFR). Results: Tumors expressed higher levels of ERβ compared to matched normal lung, whereas the reverse was true of PR. High cytoplasmic ERβ expression was identified as an independent negative prognostic predictor of overall survival (OS; HR = 1.67), and low total PR was identified as an independent negative predictor of time to progression (TTP; HR = 1.59). After adjusting for stage, age, sex, and smoking, combined high cytoplasmic ERβ and low total PR showed enhanced effects on OS (HR = 2.64) and on TTP (HR = 6.02). Further effects on OS were observed when EGFR expression was included (HR = 5.32). Patients with low cytoplasmic ERβ, low aromatase, low EGFR, and high total PR had shorter OS than patients with the opposite pattern (HR = 6.60). Contribution of these markers to survival showed no significant sex differences in a multivariable model. ERα was elevated in tumors but was not predictive of survival, and appears to represent a variant ERα protein that is only recognized by a C-terminal antibody. Conclusions: Hormonal and EGFR pathways together may contribute to lung cancer prognosis. Lung tumors with high ERβ-1/low PR may define patients with aggressive biology. A validation study is necessary to fully assess the predictive value of these markers. Clin Cancer Res; 17(1); 154–64. ©2010 AACR.

[1]  H. Uramoto,et al.  Expression of estrogen receptor beta predicts a clinical response and longer progression-free survival after treatment with EGFR-TKI for adenocarcinoma of the lung. , 2011, Lung cancer.

[2]  E. White,et al.  Lung cancer and hormone replacement therapy: association in the vitamins and lifestyle study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Takashi Suzuki,et al.  Highly concordant coexpression of aromatase and estrogen receptor beta in non-small cell lung cancer. , 2010, Human pathology.

[4]  E. Tan,et al.  Correlation between Epidermal Growth Factor Receptor Mutations and Expression of Female Hormone Receptors in East-Asian Lung Adenocarcinomas , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  G. Vlastos,et al.  Reduced Lung Cancer Mortality Risk among Breast Cancer Patients Treated with Anti-Estrogens. , 2009 .

[6]  J. Manson,et al.  Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial , 2009, The Lancet.

[7]  I. Wistuba,et al.  Immunohistochemical Expression of Estrogen and Progesterone Receptors Identifies a Subset of NSCLCs and Correlates with EGFR Mutation , 2009, Clinical Cancer Research.

[8]  J. Siegfried,et al.  Estrogen receptor beta (ERβ) subtype-specific ligands increase transcription, p44/p42 mitogen activated protein kinase (MAPK) activation and growth in human non-small cell lung cancer cells , 2009, The Journal of Steroid Biochemistry and Molecular Biology.

[9]  A. Muñoz,et al.  Nuclear receptors: Genomic and non-genomic effects converge , 2009, Cell cycle.

[10]  T. Oyama,et al.  Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Siegfried,et al.  Interim safety analysis of a phase II study of erlotinib (E) alone or combined with fulvestrant (F) in previously treated patients with advanced non-small cell lung cancer (NSCLC) , 2008 .

[12]  I. Wistuba,et al.  Aromatase expression predicts survival in women with early-stage non small cell lung cancer. , 2007, Cancer research.

[13]  C. Gotay,et al.  Toxicity and survival by sex in patients with advanced non-small cell lung carcinoma (NSCLC) on modern Southwest Oncology Group (SWOG) trials , 2007 .

[14]  J. Singer,et al.  Serum-free estradiol (E2) levels are prognostic in men with chemotherapy-naive advanced non-small cell lung cancer (NSCLC) and performance status (PS) 2 , 2007 .

[15]  R. Cerfolio,et al.  Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men. , 2006, Chest.

[16]  T. Owonikoko,et al.  Comparison of survival for non-small cell lung cancer (NSCLC) between premenopausal and postmenopausal women: An analysis of the National Surveillance, Epidemiology and End Results (SEER) Database. , 2006, Journal of Clinical Oncology.

[17]  W. Mcgregor,et al.  Gender difference in the activity but not expression of estrogen receptors α and β in human lung adenocarcinoma cells , 2006 .

[18]  M. Fishbein,et al.  Aromatase inhibitors in human lung cancer therapy. , 2005, Cancer research.

[19]  H. Nakamura,et al.  Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis , 2005, Thorax.

[20]  H. Pass,et al.  Nuclear Estrogen Receptor β in Lung Cancer: Expression and Survival Differences by Sex , 2005, Clinical Cancer Research.

[21]  Takashi Suzuki,et al.  Progesterone receptor in non-small cell lung cancer--a potent prognostic factor and possible target for endocrine therapy. , 2005, Cancer research.

[22]  Hideki Kawai,et al.  Estrogen Receptor α and β are Prognostic Factors in Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[23]  M. Fishbein,et al.  Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells , 2005, Steroids.

[24]  J. Siegfried,et al.  Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. , 2005, Cancer research.

[25]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Ping Zhang,et al.  Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. , 2003, Molecular endocrinology.

[27]  P. Lønning,et al.  Cognitive ability in childhood and cognitive decline in mid-life: longitudinal birth cohort study , 2003, BMJ : British Medical Journal.

[28]  Andrew Kramar,et al.  Progesterone Receptor Quantification as a Strong Prognostic Determinant in Postmenopausal Breast Cancer Women under Tamoxifen Therapy , 2002, Breast Cancer Research and Treatment.

[29]  J. Luketich,et al.  Human Non-Small Cell Lung Tumors and Cells Derived from Normal Lung Express Both Estrogen Receptor α and β and Show Biological Responses to Estrogen , 2002 .

[30]  L. Larsson,et al.  Estrogen and progesterone receptors in non-small cell lung cancer in 248 consecutive patients who underwent surgical resection. , 2000, Archives of pathology & laboratory medicine.

[31]  C. Lange,et al.  Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[32]  C K Osborne,et al.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  G. Stancel,et al.  Progestin regulation of vascular endothelial growth factor in human breast cancer cells. , 1998, Cancer research.

[34]  H. Hsu,et al.  Expression of estrogen and progesterone receptors in non-small-cell lung cancer: immunohistochemical study. , 1996, Anticancer research.

[35]  S. Stone,et al.  Radioimmunoassay of serum progesterone in women receiving oral contraceptive steroids. , 1972, Contraception.

[36]  B. Skov,et al.  Oestrogen receptor beta over expression in males with non-small cell lung cancer is associated with better survival. , 2008, Lung cancer.

[37]  H. Kawai,et al.  Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.